TABLE 3

Odds of death at 28 days according to the severity of respiratory impairment at randomisation

Stratification variableIntention-to-treat analysisPer-protocol analysis
MPDMOR (95% CI)p-value#MPDMOR (95% CI)p-value#
None35/337 (10.4)41/340 (12.1)0.84 (0.52–1.36)0.4924/279 (7.1)19/286 (5.6)1.32 (0.71–2.47)0.38
PaO2/FIO2 ≥200 mmHg10/150 (6.7)10/174 (5.7)1.17 (0.47–2.89)0.735/123 (4.1)3/156 (1.9)2.16 (0.51–9.22)0.30
PaO2/FIO2 <200 mmHg23/184 (12.5)31/163 (19.0)0.61 (0.34–1.09)0.1018/154 (11.7)16/128 (12.5)0.93 (0.45–1.90)0.84
Low-flow oxygen7/142 (4.9)13/174 (7.5)0.64 (0.25–1.65)0.365/122 (4.1)6/157 (3.8)1.07 (0.32–3.61)0.91
HFNC6/74 (8.1)6/45 (13.3)0.57 (0.17–1.90)0.364/66 (3.1)5/38 (13.2)0.42 (0.10–1.69)0.23
NIV22/120 (18.3)21/118 (17.8)1.04 (0.54–2.00)0.9115/90 (16.7)7/89 (7.9)2.34 (0.91–6.06)0.08

Data are presented as events n/total events n (%), unless otherwise stated. MP: methylprednisolone; DM: dexamethasone; PaO2/FIO2: ratio of arterial oxygen tension (mmHg) to inspiratory oxygen fraction; HFNC: high-flow nasal cannula; NIV: noninvasive ventilation. #: odds ratio of event among MP group versus DM group, estimated using logistic regression model.